What Causes a False Positive for Fentanyl?

False positives for fentanyl on drug tests are surprisingly common and stem from a wide range of causes, including prescription medications, over-the-counter drugs, and even the testing method itself. The problem lies primarily in the screening technology used for initial testing: immunoassays rely on antibodies that can mistake structurally similar molecules for fentanyl. The real-world consequences range from wrongful accusations in workplaces and legal proceedings to dangerous misinterpretations during pregnancy care or addiction treatment.

Why Screening Tests Get It Wrong

Most fentanyl drug tests used in hospitals, clinics, and workplace screening programs are immunoassays. These tests work by using antibodies designed to bind to fentanyl molecules in a urine sample. If enough binding occurs, the test reads as positive. The problem is that antibodies are not perfectly selective. Any molecule with a shape or charge profile close enough to fentanyl’s can fit into the same binding site and trigger a positive result. Toxicologists call this cross-reactivity, and it is the root cause of nearly every false positive on a fentanyl screen.

How often this happens depends on the specific assay and the threshold it uses to call a result positive. In one multi-site study of veterans receiving urine drug screens, the combined false-positive rate across two facilities using a lower cutoff was about 50 percent, while a third facility using a higher cutoff saw a false-positive rate of under 5 percent.¹ That is a staggering difference, and it underscores how much the screening setup itself shapes the results. A clinical evaluation of another FDA-cleared fentanyl immunoassay found a false-positive rate of 38 percent at the original cutoff, which dropped to 17 percent after the threshold was raised.² These are not rare lab curiosities. They happen routinely, which is why a positive immunoassay screening result is considered preliminary and should always be confirmed with a more precise method.

Prescription Medications Known to Cause False Positives

Several widely prescribed medications have been documented to trigger false fentanyl results. The strongest evidence involves a cluster of drugs that share structural features with fentanyl or its metabolites, even though they belong to entirely different drug classes.

Risperidone and related antipsychotics. Risperidone is the best-studied culprit. Its active metabolite, 9-hydroxyrisperidone, cross-reacts with fentanyl immunoassays. In one study evaluating emergency department urines, the immunoassay had a specificity of only 86 percent, and five of the seven false-positive samples contained risperidone or its metabolite.³ Case reports have also documented false positives in patients receiving long-acting injectable risperidone for schizophrenia.⁴ Paliperidone, the primary active metabolite of risperidone that is also marketed as its own medication, has been reported to cause the same problem.⁵ Ziprasidone, another second-generation antipsychotic, has shown similar cross-reactivity due to its structural overlap with risperidone.⁶

If you take any of these antipsychotics and face a fentanyl urine screen, a false positive is a real possibility. Knowing this ahead of time and informing the testing provider can save you significant trouble.

Trazodone. Trazodone, widely prescribed as a sleep aid and antidepressant, showed the strongest statistical association with false-positive fentanyl screens in the veterans study. Roughly 82 percent of patients with confirmed false-positive results were taking trazodone. Even at the facility using a higher, more stringent cutoff, about 78 percent of false-positive cases involved trazodone prescriptions.¹ This was a retrospective study, so it does not prove causation. But the consistency across different facilities and cutoff levels makes the association difficult to ignore.

Labetalol. This blood pressure medication, commonly used during pregnancy, has been reported to trigger false-positive fentanyl results on urine immunoassays. A case report described a pregnant patient whose fentanyl screen turned positive shortly after starting labetalol for hypertension. The consequences in this setting are especially serious: a false positive during pregnancy can lead to child protective services involvement, loss of custody, and profound disruptions to care.⁷

Over-the-Counter and Non-Prescription Substances

You do not need a prescription to take something that will trip a fentanyl screen. Diphenhydramine, the active ingredient in Benadryl and many over-the-counter sleep aids, has been shown to cause false positives on fentanyl test strips and in some clinical immunoassays.⁸ It also happens to be a common cutting agent in street heroin, which compounds the confusion in both clinical and harm reduction settings.

The veterans study also flagged several other substances that were frequently present among false-positive cases. Acetaminophen was being used by about 46 percent of those patients, nicotine replacement products by roughly 39 percent, and omeprazole (a common heartburn drug) by about 34 percent.¹ As with trazodone, these associations do not prove these substances directly caused the false positives, but the numbers were high enough to warrant attention. If you regularly use any of these and face screening, it is worth mentioning to the provider ordering your test.

False Positives on Fentanyl Test Strips

Fentanyl test strips (FTS) are lateral flow immunoassay devices that have become a key harm reduction tool. People who use drugs dip them in a solution made from a small amount of their supply to check for fentanyl contamination before use. These strips generally perform well: scoping reviews report sensitivity in the range of 96 to 98 percent and specificity around 89 percent.⁹ But that remaining gap in specificity means false positives do happen, and certain substances make them far more likely.

Lab testing has confirmed that methamphetamine, MDMA, and diphenhydramine all produce false-positive results on fentanyl test strips when present at high concentrations. Diphenhydramine capsules caused false positives at concentrations as low as 1 mg/mL, methamphetamine at about 1.5 mg/mL, and MDMA at roughly 2 mg/mL.¹⁰ Lidocaine, another common cutting agent, has also triggered false-positive readings.⁸

The critical factor is concentration. Many of the “street sample preparation” instructions found online tell people to dissolve their drug sample in a small amount of water, which can easily produce concentrations above those thresholds. Diluting the sample more thoroughly lowers the concentration of the interfering substance below its false-positive trigger point while still leaving enough fentanyl to be detected (fentanyl is active at extremely low concentrations, so even highly diluted samples will still test positive if it is present).¹⁰ If you are using FTS and testing methamphetamine, MDMA, or anything that might contain diphenhydramine, using more water than the standard instructions suggest can prevent a misleading result.

Fentanyl Analogs and the Definition Problem

Not every positive fentanyl screen that does not match confirmatory results is a simple false positive. The drug supply now contains dozens of fentanyl analogs, and whether a test strip or immunoassay detects them depends on how similar each analog’s structure is to fentanyl itself. One study testing nine fentanyl analogs against a common immunoassay kit found that acetylfentanyl and acrylfentanyl were detected almost as well as fentanyl, while furanylfentanyl and 4-fluoroisobutyrylfentanyl showed much lower cross-reactivity. Carfentanil, an extremely potent analog, was not detected at all.¹¹ Commercial fentanyl test strips showed a similar pattern, with high cross-reactivity for para-fluorofentanyl and acetylfentanyl but lower sensitivity to carfentanil and certain other analogs.¹²

This creates a definitional gray zone. If someone’s urine contains acetylfentanyl (a dangerous synthetic opioid in its own right) and the immunoassay flags it as fentanyl, is that a false positive? Technically yes, because the test is identifying the wrong molecule. Practically, though, the person was exposed to a closely related and equally dangerous substance. The bigger worry goes the other direction: analogs with low cross-reactivity, like carfentanil, could be in someone’s system and produce a false negative, giving a misleading all-clear.

Why the Cutoff Matters So Much

Every immunoassay has a cutoff concentration, the threshold above which a result is reported as positive. Lowering the cutoff makes the test more sensitive (better at catching true positives) but less specific (more prone to false positives). Raising it does the opposite. The dramatic difference between facilities in the veterans study, where false-positive rates ranged from under 5 percent at a higher cutoff to over 70 percent at a lower one, illustrates how consequential this single number can be.¹

There is no universal standard cutoff for fentanyl immunoassays. Different assay manufacturers set different defaults, and individual laboratories can adjust them. The clinical evaluation of the SEFRIA fentanyl immunoassay saw its false-positive rate cut roughly in half simply by raising the cutoff value.² This is a trade-off that labs make based on their patient population and clinical goals. A pain management clinic monitoring patients on prescribed fentanyl patches may want a low cutoff to detect non-compliance. A general hospital screening for illicit use may prefer a higher cutoff to minimize the risk of wrongly accusing patients. If you receive a positive result and believe it is wrong, asking what assay and cutoff were used is a reasonable first step.

Confirmatory Testing Is the Only Real Answer

Immunoassays are screening tools, not diagnostic ones. The standard practice after a positive fentanyl screen is to send the sample for confirmatory testing using a method called liquid chromatography-tandem mass spectrometry (LC-MS/MS). This technique identifies drugs by their exact molecular structure rather than by antibody binding, which eliminates the cross-reactivity problem entirely. When the paliperidone case described earlier went through confirmatory testing, no fentanyl or fentanyl metabolites were found.⁵

A performance evaluation comparing two FDA-approved fentanyl immunoassays against LC-MS/MS found that false positives did occur on both platforms, though they were rare when measured under controlled conditions.¹³ In real-world clinical use with diverse patient populations taking dozens of medications, the false-positive rates climb far higher than they do in a controlled lab comparison. That gap between lab performance and clinical reality is exactly why confirmatory testing exists.

Unfortunately, confirmatory testing is not always ordered. Some workplaces, legal proceedings, and even clinical settings treat the initial screen as definitive. If a positive fentanyl result does not make sense given your medication history and clinical situation, you have every right to request confirmatory testing. In many jurisdictions, you also have a legal right to it.

When False Positives Cause Real Harm

The consequences of a false-positive fentanyl test extend well beyond a bad day at the lab. In addiction medicine, patients on medication-assisted treatment who screen falsely positive for fentanyl may be discharged from their treatment programs, denied take-home doses of methadone, or flagged as non-compliant. For patients taking risperidone or trazodone alongside buprenorphine, this creates a particularly unfair trap: the very medications managing their psychiatric conditions generate the suspicious result.

In obstetric care, the labetalol situation illustrates a worst-case scenario. Pregnant patients who test positive for fentanyl may face child protective services investigations, delivery room surveillance, and potential separation from their newborns. When the positive result is caused by a blood pressure medication prescribed by the same hospital, the system is working against itself.⁷

In criminal justice settings, false positives can trigger probation violations, extended sentences, or revocation of parole. The person affected often has limited ability to challenge the result, and confirmatory testing may not be standard practice. People in these systems who take medications known to cross-react with fentanyl screens should proactively document their prescriptions and share that information with their supervising officer or attorney.

Testing Beyond Urine

Urine is by far the most common sample type for fentanyl screening, but immunoassays for other biological samples do exist. Tests have been developed for oral fluid, blood, and meconium (a newborn’s first stool, sometimes tested to check for prenatal drug exposure). These assays share the same fundamental vulnerability as urine-based tests: they rely on antibody binding and are susceptible to cross-reactivity.¹⁴ The alternative-matrix tests are not yet widely available, so most of the published data on specific cross-reacting substances comes from urine assays. If you are screened using oral fluid or blood, the general principle still applies: a positive screen should be confirmed before anyone acts on it.

One wrinkle with street drug testing using fentanyl test strips is that some false positives in the validation studies occurred when fentanyl-related substances were present but below the confirmatory method’s own cutoff of 40 ng/mL. In those cases, the test strip was reacting to trace fentanyl contamination at a level so low the confirmatory equipment classified it as negative.¹⁵ From a harm reduction standpoint, that is arguably not a false positive at all. The strip was detecting fentanyl; it just happened to be below the bar the lab equipment used. For someone trying to avoid any fentanyl exposure, the strip was giving the more cautious answer.

1
Federal Practitioner. Assessment of False-Positive Fentanyl Results on Urine Drug Screens in Veterans
2
PubMed. Understand the FDA-cleared fentanyl testing: A clinical evaluation of the SEFRIA fentanyl immunoassay
3
PubMed. Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay
4
PubMed. False-positive fentanyl screening kit results during treatment with long term injectable risperidone
5
Psychiatry Research Case Reports. False-positive fentanyl urine screening during treatment with paliperidone
6
PubMed. A false positive fentanyl result on urine drug screen in a patient treated with ziprasidone
7
PubMed. False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy
8
PubMed Central. Testing the test strips: laboratory performance of fentanyl test strips
9
PubMed Central. Fentanyl Test Strips for Harm Reduction: A Scoping Review
10
PubMed Central. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips
11
PubMed. Validation and Cross-Reactivity Data for Fentanyl Analogs With the Immunalysis Fentanyl ELISA
12
PubMed. Evaluating the sensitivity, stability, and cross-reactivity of commercial fentanyl immunoassay test strips
13
American Journal of Clinical Pathology. Performance Evaluation of Two FDA-Approved Fentanyl Immunoassays against LC-MS/MS
14
PubMed. Advances in fentanyl testing
15
PubMed Central. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples